Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page history shows a new revision (v3.4.2) replacing the previous revision (v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedThe history now shows a new revision entry (v3.4.1) added to the record, and the previous revision (v3.4.0) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page history shows a new revision label from v3.3.3 to v3.3.4, which is a minor backend update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded a footer notice 'Revision: v3.3.3'. Removed the 'HHS Vulnerability Disclosure' link and the 'Revision: v3.3.2' reference.SummaryDifference0.1%

- Check83 days agoChange DetectedThe history now includes additions for Contacts/Locations and Study Status. A deletion on 2024-11-14 removes a prior data item from the record.SummaryDifference0.3%

- Check90 days agoChange DetectedA new revision entry v3.3.2 has been added to the history, and the previous v3.2.0 entry has been removed.SummaryDifference0.1%

Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.